Extended Data Fig. 8: QPCTL deficiency leads to enhanced tumor cell control by tumor specific antibodies.

a, Schematic representation of in vivo set-up. b, Absolute number (see Fig. 4c) of recovered tumor cells from mice injected with 1:1 mixtures of WT and QPCTL KO Ba/F3-Her2 cells that were then treated with control (PBS) (-) or anti-Her2 (IgA1) ( + ). n = 6 control-treated animals; n = 6 anti-Her2-treated animals. ***P≤0.0003 by unpaired two-sided t-test. c, Ratio of in vivo killing of target cells in mice injected with a 1:1 mixture of WT and CD47-KO cells, or a 1:1 mixture of WT and QPCTL KO Ba/F3-Her2 cells, and that were either treated with control (PBS) (-) or anti-Her2 (IgA1) antibody ( + ).n = 6 control-treated animals (left graph); n = 5 anti-Her2-treated animals (left graph); n = 6 control-treated animals (right graph); n = 6 anti-Her2-treated animals (right graph). ***P < 0.0001 unpaired two-sided t-test. d, Absolute number (see Extended Data Fig. 8c) of recovered tumor cells in mice injected with a 1:1 mixture of WT and CD47 KO cells, or a 1:1 mixture of WT and QPCTL KO Ba/F3-Her2 cells, and that were either treated with control (PBS) (-) or anti-Her2 (IgA1) antibody ( + ). n = 6 control-treated animals (left graph); n = 5 anti-Her2-treated animals (left graph); n = 6 control-treated animals (right graph); n = 6 anti-Her2-treated animals (right graph). ***P < 0.0001 by one-way ANOVA with multiple comparison correction; n.s., not significant. Dots represent mice treated with control (PBS), squares represent mice treated with anti-Her2 (IgA1) (b-d) and represent mean ± s.d. of individual mice (b–d). Data are representative of two independent experiments (b) or one experiment (c,d).